All In Biotech

Free tool

FAERS Monitor: Epsolay

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 214510 or its brand name (Epsolay, Benzoyl Peroxide). Reports on generic versions are filed under their own applications.

Reports

1,390

Serious

830

60% of reports

Hospitalization

282

Death reported

49

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective147
  • rash94
  • erythema83
  • pruritus77
  • off label use72
  • fatigue65
  • pain65
  • nausea64
  • acne60
  • anxiety60
  • depression54
  • dry skin46
  • product use in unapproved indication46
  • headache45
  • diarrhoea44

Reports by year received

View as table
YearReports
20047
20054
20067
20076
200811
200911
201018
201123
201228
201332
201432
201547
201664
201763
201877
2019105
2020114
202195
2022108
2023175
2024138
2025126
202699

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,769 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
acneSignal6012.09.4595
erythemaSignal836.15.0353
dry skinSignal465.23.9153
depressionSignal543.62.899
rashSignal943.32.7148
anxietySignal603.22.589
pruritusSignal773.02.4105
product use in unapproved indicationSignal462.82.152
drug ineffective1471.71.443
pain651.61.315
fatigue651.31.03
off label use721.21.03
nausea641.21.02
headache451.10.80
diarrhoea441.00.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.